Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

Continuous monitors track blood glucose levels 24 hours a day through a sensor just under your skin, replacing finger-prick testing. They are widely funded and used overseas. The monitors alert users ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

GEORGIA AVENUE, WA, UNITED STATES, October 17, 2024 /EINPresswire / -- The latest release from Vantage <a target=_blank href= ...

High-deductible health plans can offer expanded benefits for contraception, diabetes, and breast cancer services to enrollees ...

Abbott Laboratories (ABT) reports robust sales growth in key segments despite challenges in nutrition and diagnostics.

Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

In a perspective article published in Science, Professor Jonathan Rivnay explores next-generation bioelectronic medication.

There are many reasons to own Abbott Laboratories (NYSE: ABT), but they all boil down to one thing: consistent market-beating returns.

Insulin Pumps MarketThe Insulin Pumps Market revenue were estimated at USD 5.5 Billion in 2022 and is anticipated to grow at a CAGR of 10.3% from 2022 to 2032, according to a recently published Future ...